also known as Compound 2) is a unique small-molecule agonist based on quinoxaline and allosteric modulator of GLP-1Rs with the potential to add the affinity for its receptor, first discovered by Knudsen et al
We explain interactions, kidney health, and what experts recommend
Methods Children (8-17 years) in PPT, and their caregivers (of children aged 517 years), completed three pediatric and proxy PROMIS item banks v2.0 (Pain Interference, Mobility, Upper Extremity) and two legacy instruments (Pediatric Quality of Life Inventory 4.0, NRS Pain Intensity)
S Weschawalit, S Thongthip, P Phutrakool, P Asawanonda
Now, many of them are on GLP-1s and seeing improvements to their health too